In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Merus gibt Annahme von Abstracts zur Präsentation auf der ASCO-Jahrestagung 2024 bekannt Petosemtamab in Kombination mit Pembrolizumab als 1L bei HNSCC – erste vorläufige klinische Daten für eine mündliche Kurzpräsentation ausgewählt MCLA-145 als Monotherapie oder in Kombination mit Pembrolizumab bei soliden Tumoren – erste vorläufige klinische Daten für eine mündliche Kurzpräsentation ausgewählt MCLA-129 bei NSCLC mit c-MET-Exon-14-Skipping-Mutationen – erste vorläufige klinische Daten für eine Posterpräsentation ausgewählt UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, April 25, 2...
Merus annonce les résumés acceptés pour présentation à la réunion annuelle 2024 de l’ASCO Pétosemtamab en association avec le pembrolizumab en traitement de première intention du carcinome épidermoïde de la tête et du cou : premières données cliniques provisoires sélectionnées pour une présentation orale rapide MCLA-145 en monothérapie ou en association avec le pembrolizumab dans les tumeurs solides : premières données cliniques provisoires sélectionnées pour une présentation orale rapide MCLA-129 dans le cancer bronchique non à petites cellules avec mutations conduisant à un saut de ...
Fossil Group, Inc. Announces Date for First Quarter 2024 Earnings Release and Conference Call RICHARDSON, Texas, April 24, 2024 (GLOBE NEWSWIRE) -- Fossil Group, Inc. (NASDAQ: FOSL) announced today that it will report first quarter 2024 financial results after market close on Wednesday, May 8, 2024, followed by a conference call to discuss the results at 5:00 p.m. ET the same day. The call can be accessed live on the Company’s investor relations website at /investors and will also be archived for replay. About Fossil Group, Inc. Fossil Group, Inc. is a global design, marketing, distribu...
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in solid tumors initial interim clinical data selected for rapid oral session presentation MCLA-129 in NSCLC with c-MET exon 14 skipping mutations initial interim clinical data selected for poster presentation UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Me...
Vishay Precision Group Announces Date for Its First Quarter Fiscal 2024 Earnings Conference Call MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Vishay Precision Group, Inc. (NYSE: VPG), a leader in precision measurement and sensing technologies, will release its financial results for the first quarter of fiscal 2024 before the opening of the market on Tuesday, May 7, 2024. Ziv Shoshani, chief executive officer, and Bill Clancy, chief financial officer, will host a conference call that day (Tuesday, May 7, 2024) at 9:00 a.m. U.S. eastern time. To access the conference call, interested p...
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024 UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced preclinical data on zenocutuzumab (Zeno) in cancer models with high neuregulin 1 (NRG1) expression were presented at the American Association of Cancer Research (AACR) Annual Me...
Merus stellt auf der AACR-Jahrestagung 2024 präklinische Daten als Beleg für die Wirksamkeit von Zeno in Krebsmodellen mit hoher NRG1-Expression vor UTRECHT, Niederlande, und CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) („Merus“, „das Unternehmen“, „wir“ oder „unser“), ein in der klinischer Phase tätiges Unternehmen im Bereich der Onkologie, das innovative multispezifische Antikörper in voller Länge (Biclonics® und Triclonics®) entwickelt, gab heute die Vorstellung von präklinischen Daten zu Zenocutuzumab (Zeno) in Krebsmodellen mit hoher Neuregulin 1 (NRG1)-Expres...
Merus présente des données précliniques démontrant l’efficacité de Zeno dans le traitement des modèles de cancer avec une forte expression du gène NRG1 lors de la réunion annuelle 2024 de l’AACR UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 08 avr. 2024 (GLOBE NEWSWIRE) -- (Nasdaq : MRUS) (« Merus », la « Société », « nous » ou « notre »)/« nos », une société spécialisée dans l’oncologie au stade clinique développant des anticorps de pleine longueur multispécifiques innovants (Biclonics® et Triclonics®), a annoncé aujourd’hui que des données précliniques sur le zénocutuzumab (« Zeno ») ...
Merus nimmt an einem Kamingespräch auf der 23. jährlichen Needham Virtual Healthcare Conference teil UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, April 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS), ein im klinischen Stadium tätiges Onkologieunternehmen, das innovative multispezifische Antikörper in voller Länge (Biclonics® und Triclonics®) entwickelt, hat heute bekanntgegeben, dass Dr. Bill Lundberg, President und Chief Executive Officer von Merus, am Mittwoch, 10. April 2024, um 8:45 Uhr (Eastern Time) an einem Kamingespräch auf der 23. jährlichen Needham Virtual Healthcare Confer...
Merus participera à une discussion informelle lors de la 23e conférence annuelle Needham Virtual Healthcare UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 03 avr. 2024 (GLOBE NEWSWIRE) -- (Nasdaq : MRUS), une société spécialisée dans l’oncologie au stade clinique développant des anticorps de pleine longueur multispécifiques et novateurs (Biclonics® et Triclonics®), annonce ce jour la participation de Bill Lundberg, M.D., Président et directeur général de Merus, à une discussion informelle lors de la 23e conférence annuelle Needham Virtual Healthcare qui se tiendra le mercredi 10 avril 20...
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 8:45 a.m. ET. The webcast of the presentation will be cont...
Liquidity Services Announces Second Quarter Fiscal Year 2024 Earnings Conference Call BETHESDA, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Liquidity Services (NASDAQ:LQDT), a leading global commerce company powering the circular economy, today announced that it expects to report its second quarter fiscal year 2024 results prior to market open on Thursday, May 9, 2024. Bill Angrick, Chairman and CEO, and Jorge Celaya, EVP and CFO, will then host a conference call to review the results at 10:30 AM Eastern Time. To participate in the conference call, please to receive the dial-in number and u...
Fossil Group Announces Appointment of Eugene Davis and Pamela Corrie to Board of Directors RICHARDSON, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Fossil Group, Inc. (“Fossil” or the “Company”, NASDAQ: FOSL) today announced that Eugene I. Davis has been appointed to the Board of Directors (the “Board”), effective March 24, 2024. Mr. Davis will serve as a member of the Board’s Audit Committee. The Company also announced that it has entered into a Cooperation Agreement with shareholder The Buxton Helmsley Group, Inc. (“BHG”). Pursuant to the Cooperation Agreement, the Company will welcome BH...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.